Karla Drescher;Gisela Backfisch;Liliane Unger;Andreas Haupt;Wilfried Braje;Armin Beyerbach;Sean C. Turner;John Darbyshire
发明人:
Liliane Unger,Andreas Haupt,Armin Beyerbach,Karla Drescher,Wilfried Braje,John Darbyshire,Sean C. Turner,Gisela Backfisch
申请号：
US13333702
公开号：
US20120095015A1
申请日:
2011.12.21
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms； R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl； R1a is hydrogen or C1-C4 alkyl； and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl； and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceutically composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.
